More on GALT
Data
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $2.83 |
|
|||
| Open | $2.82 | ||||
| 52 Wk High | $3.05 | ||||
| 52 Wk Low | $0.49 | ||||
| Day High | $2.99 | ||||
| Day Low | $2.80 | ||||
| P/E | N/A | ||||
| EPS | $-1.32 | ||||
| Volume | 124,075 | ||||
- Form 4 GALECTIN THERAPEUTICS For: May 26 Filed by: Jamil Khurram
- Galectin Therapeutics Presents New EASL 2026 Oral and Poster Analyses Demonstrating Belapectin’s Potential to Modify Disease Progression in Advanced MASH Cirrhosis
- Galectin Therapeutics Reports March 31, 2026 Financial Results and Provides Business Update
- Form 8-K GALECTIN THERAPEUTICS For: May 15
- Form 10-Q GALECTIN THERAPEUTICS For: Mar 31
- Galectin Therapeutics publishes belapectin trial results in Hepatology
- Galectin Therapeutics Announces Publication of NAVIGATE Phase 2b Trial Results for Belapectin in the Journal of Hepatology
- Form EFFECT GALECTIN THERAPEUTICS
- Galectin Therapeutics (GALT) files mixed shelf
- Form S-3 GALECTIN THERAPEUTICS
Entities mentioned with GALT
- FDA | View Related Stories »
- Earnings | View Related Stories »
- Dividend | View Related Stories »
- Definitive Agreement | View Related Stories »
- H.C. Wainwright | View Related Stories »
- S3 | View Related Stories »
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- Show More...
